Found: 12
Select item for more details and to access through your institution.
A 96‐week, double‐blind, randomized controlled trial comparing bexagliflozin to glimepiride as an adjunct to metformin for the treatment of type 2 diabetes in adults.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 1, p. 293, doi. 10.1111/dom.14875
- By:
- Publication type:
- Article
Ultra rapid lispro improves postprandial glucose control compared with lispro in patients with type 1 diabetes: Results from the 26‐week PRONTO‐T1D study.
- Published in:
- Diabetes, Obesity & Metabolism, 2020, v. 22, n. 10, p. 1799, doi. 10.1111/dom.14100
- By:
- Publication type:
- Article
Intramyocellular Lipids: Anthropometric Determinants and Relationships with Maximal Aerobic Capacity and Insulin Sensitivity.
- Published in:
- Journal of Clinical Endocrinology & Metabolism, 2003, v. 88, n. 4, p. 1785, doi. 10.1210/jc.2002-021674
- By:
- Publication type:
- Article
Lipid content in the musculature of the lower leg assessed by fat selective MRI: Intra- and interindividual differences and correlation with anthropometric and metabolic data.
- Published in:
- Journal of Magnetic Resonance Imaging, 2003, v. 17, n. 3, p. 350, doi. 10.1002/jmri.10255
- By:
- Publication type:
- Article
Effect of glimepiride on insulin-stimulated glycogen synthesis in cultured human skeletal muscle cells: a comparison to glibenclamide.
- Published in:
- 2002
- By:
- Publication type:
- journal article
Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial.
- Published in:
- JAMA: Journal of the American Medical Association, 2022, v. 327, n. 6, p. 534, doi. 10.1001/jama.2022.0078
- By:
- Publication type:
- Article
Effects of intravenous and dietary lipid challenge on intramyocellular lipid content and the relation with insulin sensitivity in humans.
- Published in:
- 2001
- By:
- Publication type:
- journal article
Long-Term Efficacy and Safety of Ultra Rapid Lispro (URLi) in Adults with Type 1 Diabetes: The PRONTO-T1D Extension.
- Published in:
- Diabetes Therapy, 2021, v. 12, n. 2, p. 569, doi. 10.1007/s13300-020-00987-8
- By:
- Publication type:
- Article
Novel Once-Weekly Basal Insulin Fc Achieved Similar Glycemic Control With a Safety Profile Comparable to Insulin Degludec in Patients With Type 1 Diabetes.
- Published in:
- Diabetes Care, 2023, v. 46, n. 5, p. 1052, doi. 10.2337/dc22-2395
- By:
- Publication type:
- Article
80-LB: Tirzepatide, a Dual GIP/GLP-1 Receptor Agonist, Is Effective and Safe When Added to Basal Insulin for Treatment of Type 2 Diabetes (SURPASS-5).
- Published in:
- Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-80-LB
- By:
- Publication type:
- Article
232-OR: Long-Term Safety and Efficacy of Ultra-Rapid Lispro (URLi) in PRONTO-T1D.
- Published in:
- Diabetes, 2020, v. 69, p. N.PAG, doi. 10.2337/db20-232-OR
- By:
- Publication type:
- Article
144-OR: Ultra Rapid Lispro (URLi) Improves Postprandial Glucose (PPG) Control vs. Humalog (Lispro) in T1D: PRONTO-T1D Study.
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-144-OR
- By:
- Publication type:
- Article